CSIR‑IICT’s Phytopharmaceutical for Diabetic Foot Ulcers
Overview
Researchers at the CSIR‑Indian Institute of Chemical Technology (CSIR‑IICT) have created a plant‑based drug from the medicinal herb Gymnema sylvestre. The formulation is aimed at treating diabetic foot ulcers, a serious complication of diabetes, and may also help other chronic wounds and inflammatory skin disorders.
Key Developments
- Project led by Anthony Addlagatta with contributions from Srigiridhar Kotamraju and Aruna Jangam.
- Supported under the CSIR Phytopharmaceutical Mission Phase III.
- Secured patent protection in India and abroad.
- Completed botanical standardisation, pharmacology, mechanism‑of‑action, analytical characterisation, pharmacokinetics, formulation, stability and safety studies.
- Compiled an IND‑ready data package.
- Technology transfer to Viridis Biopharma Pvt. Ltd. for clinical development and regulatory filing with CDSCO and the FDA.
Important Facts
The drug development pathway followed strict regulatory guidelines, ensuring the product meets safety and efficacy standards required for human trials. Patent protection enhances commercial viability and encourages further investment in botanical drug research. The collaboration between a public research institute and a private biotech firm exemplifies the “academia‑industry” model promoted by the Indian government.
Exam Relevance
Understanding this case helps aspirants in several GS papers:
- GS3 – Science & Technology: Shows how public research bodies translate basic science into market‑ready products.
- GS3 – Health: Highlights the burden of diabetic foot ulcers and the need for affordable therapies.
- GS3 – Industry & Trade: Illustrates technology transfer, patent strategy, and the role of biotech startups in the Indian economy.
- GS4 – Ethics: Raises questions on equitable access to life‑saving medicines and the responsibility of the state to promote indigenous drug development.
Way Forward
Viridis Biopharma will file the required dossiers with CDSCO and the FDA, conduct Phase I/II clinical trials, and seek market approval. Successful commercialization could set a precedent for other phytopharmaceuticals, reduce dependence on imported wound‑care products, and strengthen India’s position in the global biotech arena.